Gilead Sciences, Inc. (NASDAQ:GILD) CEO Sells $1,139,400.00 in Stock

Key Points

• Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of stock at an average price of $113.94, totaling $1,139,400, reducing his ownership by 1.62%.
• As of the latest trading, Gilead shares rose 1.1% to $114.23, with a market cap of $142.09 billion and a P/E ratio of 24.05.
• Institutional investors now hold 83.67% of Gilead's stock, indicating strong institutional interest and potential confidence in the company’s future performance.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Daniel Patrick O'day also recently made the following trade(s):

• On Monday, June 30th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00.
• On Friday, May 30th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00.

Gilead Sciences Trading Up 0.6%

GILD stock traded up $0.71 during trading on Friday, hitting $113.00. The company had a trading volume of 1,730,954 shares, compared to its average volume of 8,405,442. The firm has a market capitalization of $140.57 billion, a P/E ratio of 23.80, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 52-week low of $72.43 and a 52-week high of $119.96. The company has a 50 day simple moving average of $110.40 and a 200-day simple moving average of $106.55. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $112.36.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after buying an additional 1,942,433 shares in the last quarter. FMR LLC boosted its holdings in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.